Mitsubishi UFJ Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,235	Closed	-$226K	–	1169
2021 Q3	$226K	Hold	11,235	–	–	﹤0.01%	1043
2021 Q2	$419K	Sell	11,235 -5,048	-31%	-$155K	﹤0.01%	979
2021 Q1	$416K	Buy	16,283 +5,635	+53%	+$144K	﹤0.01%	909
2020 Q4	$235K	Buy	10,648 +2,270	+27%	+$50K	﹤0.01%	937
2020 Q3	$151K	Sell	8,378 -361	-4%	-$7.47K	﹤0.01%	926
2020 Q2	$222K	Buy	8,739 +1,436	+20%	+$30.9K	﹤0.01%	875
2020 Q1	$134K	Buy	7,303 +1,547	+27%	+$30.1K	﹤0.01%	900
2019 Q4	$122K	Sell	5,756 -6,584	-53%	-$132K	﹤0.01%	937
2019 Q3	$177K	Buy	12,340 +2,374	+24%	+$33.9K	﹤0.01%	840
2019 Q2	$157K	Sell	9,966 -1,652	-14%	-$22.5K	﹤0.01%	857
2019 Q1	$170K	Buy	11,618 +945	+9%	+$10.9K	﹤0.01%	814
2018 Q4	$116K	Buy	10,673 +163	+2%	+$2.14K	﹤0.01%	827
2018 Q3	$160K	Buy	+10,510	New	+$153K	﹤0.01%	795

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Mitsubishi UFJ Asset Management's DRNA Position: Q4 2021 in Review

Mitsubishi UFJ Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 11,235 shares — an estimated $226K sold.

Mitsubishi UFJ Asset Management first reported a position in DRNA in Q3 2018 and held it in 13 quarters. The position peaked at $419K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Mitsubishi UFJ Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Mitsubishi UFJ Asset Management sold 11,235 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $226K.
Mitsubishi UFJ Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 13 quarters.
Mitsubishi UFJ Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $419K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2021, filed 7 Feb 2022.